GlycoNex
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company's development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under preclinical stage; GNX203, glycan-directed anti… Read more
GlycoNex (4168) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.017x
Based on the latest financial reports, GlycoNex (4168) has a cash flow conversion efficiency ratio of -0.017x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-17.29 Million) by net assets (NT$1.01 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GlycoNex - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how GlycoNex's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
GlycoNex Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GlycoNex ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GRUPO ECOENER EO -32
F:89W
|
N/A |
|
Bertrandt AG
LSE:0NYZ
|
0.047x |
|
ESTsoft Corp
KQ:047560
|
-0.074x |
|
TC Bancshares Inc
NASDAQ:TCBC
|
0.018x |
|
ECO ANIMAL HLTH GR.LS-05
F:LWA
|
N/A |
|
Lundin Energy AB
PINK:LNDNF
|
-0.005x |
|
EuroHold Bulgaria AD
WAR:EHG
|
0.332x |
|
MNULF
PINK:MNULF
|
N/A |
Annual Cash Flow Conversion Efficiency for GlycoNex (2017–2024)
The table below shows the annual cash flow conversion efficiency of GlycoNex from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.05 Billion | NT$-221.97 Million | -0.212x | -47.20% |
| 2023-12-31 | NT$1.28 Billion | NT$-183.92 Million | -0.144x | -24.32% |
| 2022-12-31 | NT$1.45 Billion | NT$-167.55 Million | -0.116x | -11.81% |
| 2021-12-31 | NT$1.36 Billion | NT$-140.86 Million | -0.104x | -9.61% |
| 2020-12-31 | NT$1.54 Billion | NT$-145.59 Million | -0.095x | +31.50% |
| 2019-12-31 | NT$1.30 Billion | NT$-179.58 Million | -0.138x | -17.31% |
| 2018-12-31 | NT$1.53 Billion | NT$-180.34 Million | -0.118x | -452.73% |
| 2017-12-31 | NT$1.84 Billion | NT$61.43 Million | 0.033x | -- |